Quantification of risk factors for herpes zoster: Population based case-control study

BMJ (Online)

Volumn 348, Issue , 2014, Pages

  Forbes, Harriet J ^a   Bhaskaran, Krishnan ^a   Thomas, Sara L ^a   Smeeth, Liam ^a   Clayton, Tim ^a   Langan, Sinéad M ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; ASTHMA; CHRONIC KIDNEY DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; FEMALE; GROUPS BY AGE; HERPES ZOSTER; HUMAN; INFECTION RISK; INFLAMMATORY BOWEL DISEASE; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MYELOMA; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; VERY ELDERLY; YOUNG ADULT; ADOLESCENT; AGE; AUTOIMMUNE DISEASES; CASE CONTROL STUDY; CHRONIC KIDNEY FAILURE; COMPLICATION; DIABETES MELLITUS; GREAT BRITAIN; IMMUNIZATION; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; OBESITY; STATISTICAL MODEL; SYSTEMIC LUPUS ERYTHEMATOSUS;

VARICELLA ZOSTER VACCINE;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; CASE-CONTROL STUDIES; DEPRESSION; DIABETES COMPLICATIONS; FEMALE; GREAT BRITAIN; HERPES ZOSTER; HERPES ZOSTER VACCINE; HUMANS; IMMUNIZATION; IMMUNOCOMPROMISED HOST; INFLAMMATORY BOWEL DISEASES; LOGISTIC MODELS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; OVERWEIGHT; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS;

EID: 84901020175     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.g2911     Document Type: Article

References (55)

1. Hope-Simpson RE. Postherpetic neuralgia. J R Coll Gen Pract 1975;25:571-5.
2. Thomas SL, Hall AJ. What does epidemiology tell us about risk factors for herpes zoster? Lancet Infect Dis 2004;4:26-33. (Pubitemid 38057055)
3. Gnann JW Jr, Whitley RJ. Clinical practice: herpes zoster. N Engl J Med 2002;347:340-6.
4. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005;352:2271-84.
5. Van Hoek AJ, Gay N, Melegaro A, Opstelten W, Edmunds WJ. Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales. Vaccine 2009;27:1454-67.
6. Gauthier A, Breuer J, Carrington D, Martin M, Remy V. Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom. Epidemiol Infect 2009;137:38-47.
7. Veetil BM, Myasoedova E, Matteson EL, Gabriel SE, Green AB, Crowson CS. Incidence and time trends of herpes zoster in rheumatoid arthritis: a population-based cohort study. Arthritis Care Res 2013;65:854-61.
8. Nagasawa K, Yamauchi Y, Tada Y, Kusaba T, Niho Y, Yoshikawa H. High incidence of herpes zoster in patients with systemic lupus erythematosus: an immunological analysis. Ann Rheum Dis 1990;49:630-3. (Pubitemid 20225437)
9. Long MD, Martin C, Sandler RS, Kappelman MD. Increased risk of herpes zoster among 108 604 patients with inflammatory bowel disease. Aliment Pharmacol Ther 2013;37:420-9.
10. Heymann AD, Chodick G, Karpati T, Kamer L, Kremer E, Green MS, et al., Diabetes as a risk factor for herpes zoster infection: results of a population-based study in Israel. Infection 2008;36:226-30.
11. Joesoef RM, Harpaz R, Leung J, Bialek SR. Chronic medical conditions as risk factors for herpes zoster. Mayo Clin Proc 2012;87:961-7.
12. Yang YW, Chen YH, Wang KH, Wang CY, Lin HW. Risk of herpes zoster among patients with chronic obstructive pulmonary disease: a population-based study. CMAJ 2011;183:E275-80.
13. Langan SM, Smeeth L, Margolis DJ, Thomas SL. Herpes zoster vaccine effectiveness against incident herpes zoster and post-herpetic neuralgia in an older US population: a cohort study. PLoS Med 2013;10:e1001420.
14. Kuo CC, Lee CT, Lee IM, Ho SC, Yang CY. Risk of herpes zoster in patients treated with long-term hemodialysis: a matched cohort study. Am J Kidney Dis 2012;59:428-33.
15. Wu MY, Hsu YH, Su CL, Lin YF, Lin HW. Risk of herpes zoster in CKD: a matched-cohort study based on administrative data. Am J Kidney Dis 2012;60:548-52.
16. Kim BS, Mehra S, Yawn B, Grose C, Tarrell R, Lahr B, et al. Increased risk of herpes zoster in children with asthma: a population-based case-control study. J Pediatr 2013;163:816-21.
17. Yang YW, Chen YH, Lin HW. Risk of herpes zoster among patients with psychiatric diseases: a population-based study. J Eur Acad Dermatol Venereol 2011;25:447-53.
18. NHS Connecting for Health. Read codes. 2011. www.connectingforhealth.nhs. uk/systemsandservices/data/uktc/readcodes.
19. Campbell J, Dedman DJ, Eaton SC, Gallagher AM, Williams TJ. Is the CPRD GOLD population comparable to the U.K. population? Pharmacoepidemiol Drug Saf 2013;22(s1):280.
20. Lewis JD, Bilker WB, Weinstein RB, Strom BL. The relationship between time since registration and measured incidence rates in the General Practice Research Database. Pharmacoepidemiol Drug Saf 2005;14:443-51. (Pubitemid 40990739)
21. Pearce N. What does the odds ratio estimate in a case-control study? Int J Epidemiol 1993;22:1189-92. (Pubitemid 24025700)
22. Rodrigues L, Kirkwood BR. Case-control designs in the study of common diseases: updates on the demise of the rare disease assumption and the choice of sampling scheme for controls. Int J Epidemiol 1990;19:205-13. (Pubitemid 20126858)
23. Centers for Disease Control and Prevention. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). CDC, 2008.
24. Ernst P, Dell'Aniello S, Mikaeloff Y, Suissa S. Risk of herpes zoster in patients prescribed inhaled corticosteroids: a cohort study. BMC Pulm Med 2011;11:59.
25. Suissa S, Dell'aniello S, Vahey S, Renoux C. Time-window bias in case-control studies: statins and lung cancer. Epidemiology 2011;22:228-31.
26. Investing in general practice: the new general medical services contract. 2004. www.gpcwm.org.uk/wp-content/uploads/file/ INVESTING%20IN%20GENERAL%20PRACTICE/Investing-in-Gen-Pract-the-new-GMS-Contract. pdf.
27. White IR, Royston P, Wood AM. Multiple imputation using chained equations: issues and guidance for practice. Stat Med 2011;30:377-99.
28. Tyring SK, Diaz-Mitoma F, Padget LG, Nunez M, Poland G, Cassidy WM, et al. Safety and tolerability of a high-potency zoster vaccine in adults >/= 50 or years of age. Vaccine 2007;25:1877-83. (Pubitemid 46176321)
29. Lu PJ, Euler GL, Jumaan AO, Harpaz R. Herpes zoster vaccination among adults aged 60 years or older in the United States, 2007: uptake of the first new vaccine to target seniors. Vaccine 2009;27:882-7.
30. Hope-Simpson RE. The nature of herpes zoster: a long-term study and a new hypothesis. Proc R Soc Med 1965;58:9-20.
31. Opstelten W, van Loon AM, Schuller M, van Wijck AJ, van Essen GA, Moons KG, et al. Clinical diagnosis of herpes zoster in family practice. Ann Fam Med 2007;5:305-9. (Pubitemid 47294846)
32. Rubben A, Baron JM, Grussendorf-Conen EI. Routine detection of herpes simplex virus and varicella zoster virus by polymerase chain reaction reveals that initial herpes zoster is frequently misdiagnosed as herpes simplex. Br J Dermatol 1997;137:259-61. (Pubitemid 27333362)
33. Smitten AL, Choi HK, Hochberg MC, Suissa S, Simon TA, Testa MA, et al. The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom. Arthritis Rheum 2007;57:1431-8. (Pubitemid 350308841)
34. Lasserre A, Blaizeau F, Gorwood P, Bloch K, Chauvin P, Liard F, et al. Herpes zoster: family history and psychological stress-case-control study. J Clin Virol 2012;55:153-7.
35. Jih JS, Chen YJ, Lin MW, Chen YC, Chen TJ, Huang YL, et al, Epidemiological features and costs of herpes zoster in Taiwan: a national study 2000 to 2006. Acta Derm Venereol 2009;89:612-6.
36. Geerlings SE, Hoepelman AI. Immune dysfunction in patients with diabetes mellitus (DM). FEMS Immunol Med Microbiol 1999;26:259-65.
37. Oldroyd J, Banerjee M, Heald A, Cruickshank K. Diabetes and ethnic minorities. Postgrad Med J 2005;81:486-90. (Pubitemid 41160589)
38. Yang IA, Clarke MS, Sim EH, Fong KM. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012:(7):CD002991.
39. Cupps TR, Fauci AS. Corticosteroid-mediated immunoregulation in man. Immunol Rev 1982;65:133-55. (Pubitemid 12068797)
40. Brusselle GG, Joos GF, Bracke KR. New insights into the immunology of chronic obstructive pulmonary disease. Lancet 2011;378:1015-26.
41. Takabatake N, Sata M, Abe S, Inoue S, Saito H, Yuki H, et al. Impaired systemic cell-mediated immunity and increased susceptibility to acute respiratory tract infections in patients with COPD. Respir Med 2005;99:485-92. (Pubitemid 40347833)
42. Contoli M, Message SD, Laza-Stanca V, Edwards MR, Wark PA, Bartlett NW, et al. Role of deficient type III interferon-lambda production in asthma exacerbations. Nat Med 2006;12:1023-6. (Pubitemid 44353382)
43. Hauser AB, Stinghen AE, Kato S, Bucharles S, Aita C, Yuzawa Y, et al. Characteristics and causes of immune dysfunction related to uremia and dialysis. Perit Dial Int 2008;28(suppl 3):S183-7.
44. Kusnecov AW, Rabin BS. Stressor-induced alterations of immune function: mechanisms and issues. Int Arch Allergy Immunol 1994;105:107-21. (Pubitemid 24302225)
45. Irwin M, Costlow C, Williams H, Artin KH, Chan CY, Stinson DL, et al. Cellular immunity to varicella-zoster virus in patients with major depression [correction in: J Infect Dis 1999;179:753]. J Infect Dis 1998;178(suppl 1):S104-8. (Pubitemid 28514282)
46. Irwin MR., Levin MJ, Laudenslager ML, Olmstead R, Lucko A, Lang N, et al. Varicella zoster virus-specific immune responses to a herpes zoster vaccine in elderly recipients with major depression and the impact of antidepressant medications. Clin Infect Dis 2013;56:1085-93.
47. Blank LJ, Polydefkis MJ, Moore RD, Gebo KA. Herpes zoster among persons living with HIV in the current antiretroviral therapy era. J Acquir Immune Defic Syndr 2012;61:203-7.
48. Gebo KA, Kalyani R, Moore RD, Polydefkis MJ. The incidence of, risk factors for, and sequelae of herpes zoster among HIV patients in the highly active antiretroviral therapy era. J Acquir Immune Defic Syndr 2005;40:169-74. (Pubitemid 41395715)
49. Morgan D, Mahe C, Malamba, Okongo M, Mayanja B, Whitworth J. Herpes zoster and HIV-1 infection in a rural Ugandan cohort. AIDS 2001;15:223-9. (Pubitemid 32142298)
50. Drolet M, Brisson M, Schmader K, Levin M, Johnson R, Oxman M, et al. Predictors of postherpetic neuralgia among patients with herpes zoster: a prospective study. J Pain 2010;11:1211-21.
51. Choo PW, Galil K, Donahue JG, Walker AM, Spiegelman D, Platt R. Risk factors for postherpetic neuralgia. Arch Intern Med 1997;157:1217-24. (Pubitemid 27251649)
52. Katz J, McDermott MP, Cooper EM, Walther RR, Sweeney EW, Dworkin RH. Psychosocial risk factors for postherpetic neuralgia: a prospective study of patients with herpes zoster. J Pain 2005;6:782-90. (Pubitemid 41739595)
53. Kanbayashi Y, Onishi K, Fukazawa K, Okamoto K, Ueno H, Takagi T, et al. Predictive factors for postherpetic neuralgia using ordered logistic regression analysis. Clin J Pain 2012;28:712-4.
54. Opstelten W, Mauritz JW, de Wit NJ, van Wijck AJ, Stalman WA, van Essen GA. Herpes zoster and postherpetic neuralgia: incidence and risk indicators using a general practice research database. Fam Pract 2002;19:471-5. (Pubitemid 35244231)
55. Dworkin RH, Hartstein G, Rosner HL, Walther RR, Sweeney EW, Brand L. A high-risk method for studying psychosocial antecendents of chronic pain: the prospective investigation of herpes zoster. J Abnorm Psychol 1992;101:200-5.